In this issue of Cancer Cell, Brenner et al. describe that the poly-(ADP) ribose polymerase (PARP) may mediate ERG function and that PARP blockade has antitumor activity in ETS gene-rearranged prostate cancer models. These data support the clinical evaluation of PARP inhibitors for treating ETS gene-rearranged prostate cancers. © 2011 Elsevier Inc.
Sebastian de Bono, J., Sandhu, S., & Attard, G. (2011, May 17). Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. Cancer Cell. https://doi.org/10.1016/j.ccr.2011.05.003